Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Industry News

Miracor Medical Starts PiCSO-AMI-I Randomized Study in EU

July 25, 2019

News Industry News

Ortho Receives CE Mark for Enhanced VITROS® Immunodiagnostic Products NT-proBNP II Assay, an Aid in Diagnosing and Assessing Heart Failure

July 23, 2019

News Industry News

New study finds both components of blood pressure predict heart attack, stroke risk

July 17, 2019

News Industry News

Ortho's VITROS® High Sensitivity Troponin I Assay for the Diagnosis of Heart Attack Now CE Marked, Available in EU Countries

April 16, 2019

News Industry News

BioVentrix Receives CE Marking Certification for Revivent TC™, the First Minimally Invasive Heart Failure Treatment to Restore the Left Ventricle

June 27, 2016

News Industry News

Capricor Therapeutics Reports Positive 12-Month Data from the DYNAMIC Clinical Trial

June 17, 2016

News Industry News

Secondary Analysis of EXAMINE Trial Finds Highest Risk of Cardiovascular Death for Patients Previously Hospitalized with Heart Failure

June 13, 2016

News Industry News

Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy

June 16, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Industry News

Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cell Therapy in Patients with Ischemic Heart Failure

June 02, 2015

Advertisement

Miracor Medical Starts PiCSO-AMI-I Randomized Study in EU

Ortho Receives CE Mark for Enhanced VITROS® Immunodiagnostic Products NT-proBNP II Assay, an Aid in Diagnosing and Assessing Heart Failure

New study finds both components of blood pressure predict heart attack, stroke risk

Ortho's VITROS® High Sensitivity Troponin I Assay for the Diagnosis of Heart Attack Now CE Marked, Available in EU Countries

BioVentrix Receives CE Marking Certification for Revivent TC™, the First Minimally Invasive Heart Failure Treatment to Restore the Left Ventricle

Capricor Therapeutics Reports Positive 12-Month Data from the DYNAMIC Clinical Trial

Secondary Analysis of EXAMINE Trial Finds Highest Risk of Cardiovascular Death for Patients Previously Hospitalized with Heart Failure

Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cell Therapy in Patients with Ischemic Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content